AI Just Got FDA Clearance to Detect Lung Cancer — What That Means for Pulmonary Medicine
In February 2026, the FDA cleared the first AI-powered device able to both detect and characterize lung cancer on low-dose CT scans in a single product — a milestone the manufacturer says could help large-scale screening reach the roughly 14.5 million Americans currently eligible. It's a concrete signal of something pulmonary medicine has been building toward for several years: AI is no longer a research curiosity in this specialty, it is showing up in FDA-cleared clinical tools with real sensitivity and specificity numbers behind them.
Opportunities, Risks, and Future Directions of AI in Pulmonary Medicine, newly published by IGI Global Scientific Publishing and edited by Rahul K. Patel and Dr. Jayant B. Mehta, a practicing pulmonologist of more than 20 years, gives libraries and practitioners a specialty-specific reference rather than a generic AI-in-healthcare survey. Across 11 chapters, it covers the clinical applications moving fastest right now alongside the risks that come with them.
Three areas the book covers in depth:
- Lung cancer detection and risk stratification — multiple chapters address AI-powered diagnosis, early detection, and radiomics, directly relevant to the kind of screening tools now reaching FDA clearance.
- Critical care and ventilation — closed-loop systems and multimodal ICU decision support for ARDS and respiratory failure, an area where AI assistance is moving from research into bedside pilots.
- Chronic disease management — machine learning applications for asthma and COPD prediction, remote monitoring, and outcome tracking.
The book doesn't stop at applications. A closing chapter and cross-cutting sections on ethics, data governance, liability, and global equity address the questions institutions have to answer before adopting these tools — not just whether an algorithm works, but who is accountable when it doesn't, and whether the populations it was trained on match the patients it will be used on.
For academic medical libraries, this fills a gap that general "AI in healthcare" titles don't: specialty depth. For pulmonologists, radiologists, and health AI researchers, it's current enough to engage directly with tools reaching the clinic in 2026.
CLNZ Books ships this hardcover edition worldwide, with secure payment by card, PayPal, or international bank transfer, and institutional invoicing available on request.
Q&A
How is AI currently being used in pulmonary medicine?
AI is applied across lung imaging analysis, cancer detection, ventilator decision support in critical care, and monitoring of chronic conditions such as asthma and COPD.
What risks does this book address around AI in respiratory care?
Chapters cover data privacy, algorithmic bias, clinical reliability, and the legal and ethical implications of deploying AI tools in pulmonary practice.
Does the book cover lung cancer specifically?
Yes — several chapters focus on AI-powered lung cancer diagnosis, early detection, risk stratification, and radiomics.
Who is this book written for?
Pulmonologists, radiologists, healthcare professionals, biomedical engineers, academic medical libraries, and researchers working on AI applications in respiratory medicine.
Where can I buy Opportunities, Risks, and Future Directions of AI in Pulmonary Medicine?
Directly from CLNZ Books, with worldwide shipping and secure payment.